Malignant Pleural Mesothelioma - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Malignant Pleural Mesothelioma - Pipeline Review, H2 2015’, provides an overview of the Malignant Pleural Mesothelioma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Malignant Pleural Mesothelioma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Malignant Pleural Mesothelioma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Malignant Pleural Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Malignant Pleural Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Malignant Pleural Mesothelioma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Malignant Pleural Mesothelioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Introduction
- Global Markets Direct Report Coverage
- Malignant Pleural Mesothelioma Overview
- Therapeutics Development
- Pipeline Products for Malignant Pleural Mesothelioma - Overview
- Pipeline Products for Malignant Pleural Mesothelioma - Comparative Analysis
- Malignant Pleural Mesothelioma - Therapeutics under Development by Companies
- Malignant Pleural Mesothelioma - Therapeutics under Investigation by Universities/Institutes
- Malignant Pleural Mesothelioma - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Malignant Pleural Mesothelioma - Products under Development by Companies
- Malignant Pleural Mesothelioma - Products under Investigation by Universities/Institutes
- Malignant Pleural Mesothelioma - Companies Involved in Therapeutics Development
- Aduro BioTech, Inc.
- Advantagene, Inc.
- Amphera BV
- AnGes MG, Inc.
- ArQule, Inc.
- Bayer AG
- Biogen, Inc.
- Bionomics Limited
- Boehringer Ingelheim GmbH
- Boston Biomedical, Inc.
- Bristol-Myers Squibb Company
- CanBas Co., Ltd.
- Concordia Healthcare Corp.
- EnGeneIC Ltd
- F. Hoffmann-La Roche Ltd.
- Five Prime Therapeutics, Inc.
- Genelux Corporation
- GlaxoSmithKline Plc
- Juno Therapeutics Inc.
- MedImmune, LLC
- Merck & Co., Inc.
- MolMed S.p.A.
- Morphotek, Inc.
- Novartis AG
- Ono Pharmaceutical Co., Ltd.
- Oxford BioMedica Plc
- Pfizer Inc.
- Pharma Mar, S.A.
- Polaris Pharmaceuticals, Inc.
- Synta Pharmaceuticals Corp.
- Verastem, Inc.
- Virttu Biologics Limited
- Malignant Pleural Mesothelioma - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Ad5-SGE-REIC/Dkk3 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- amatuximab - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- anetumab ravtansine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ascrinvacumab - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- bevacizumab - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BG-00001 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BMS-986148 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BNC-105 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- CBP-501 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Cell Therapy 1 for Oncology - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Cell Therapy for Malignant Pleural Mesothelioma and Advanced Leukemia - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- CRS-207 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- FP-1039 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ganetespib - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- GEN-0101 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Gene Therapy for Malignant Pleural Mesothelioma - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- GLONC-1 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- GSK-2256098 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- HSV-1716 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- iCasp9M28z - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- JTCR-016 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MesoCancerVac - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MesoCART - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- napabucasin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- NGR-hTNF - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- nintedanib - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- nivolumab - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- pegargiminase - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- pembrolizumab - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- porfimer sodium - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- rAd-IFN - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Metastatic Lung Cancer - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- TargomiRs - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- tivantinib - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- trabectedin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- tremelimumab - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- TroVax - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- VS-5584 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Malignant Pleural Mesothelioma - Recent Pipeline Updates
- Malignant Pleural Mesothelioma - Dormant Projects
- Malignant Pleural Mesothelioma - Discontinued Products
- Malignant Pleural Mesothelioma - Product Development Milestones
- Featured News & Press Releases
- Sep 26, 2015: Aduro Biotech Announces Phase 1b Mesothelioma Trial Featured in Spotlight Poster at ESMO/ECC
- Sep 09, 2015: Five Prime Therapeutics Announces Initial Data From Ongoing Phase 1b Trial of FP-1039 in Squamous Non Small Cell Lung Cancer and Mesothelioma
- May 14, 2015: PharmaMar announces new advances in oncology at ASCO 2015 for its compound YONDELIS in small cell lung cancer, soft tissue sarcoma, and mesothelioma
- Apr 23, 2015: Mesothelioma Immunotherapy Vaccine Receives Orphan Drug Designation from FDA, Baron & Budd Reports
- Apr 19, 2015: Early Findings with KEYTRUDA (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting
- Apr 19, 2015: Immunotherapy drug pembrolizumab shows promise for mesothelioma patients
- Mar 26, 2015: Aduro Receives Orphan Drug Designation for CRS-207 in Mesothelioma
- Mar 18, 2015: New Data Investigating Merck’s KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015
- Jan 20, 2015: Verastem Doses First Patient In Phase 1 Clinical Trial Evaluating VS-5584 In Combination With VS-6063 In Mesothelioma
- Jan 20, 2015: Verastem Receives Orphan Medicinal Product Designation from the European Commission for VS-5584 in Mesothelioma
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Malignant Pleural Mesothelioma, H2 2015
- Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Number of Products under Investigation by Universities/Institutes, H2 2015
- Comparative Analysis by Late Stage Development, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Comparative Analysis by Early Stage Development, H2 2015
- Products under Development by Companies, H2 2015
- Products under Development by Companies, H2 2015 (Contd...1)
- Products under Development by Companies, H2 2015 (Contd...2)
- Products under Investigation by Universities/Institutes, H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Aduro BioTech, Inc., H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Advantagene, Inc., H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Amphera BV, H2 2015
- Malignant Pleural Mesothelioma - Pipeline by AnGes MG, Inc., H2 2015
- Malignant Pleural Mesothelioma - Pipeline by ArQule, Inc., H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Bayer AG, H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Biogen, Inc., H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Bionomics Limited, H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Boston Biomedical, Inc., H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H2 2015
- Malignant Pleural Mesothelioma - Pipeline by CanBas Co., Ltd., H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Concordia Healthcare Corp., H2 2015
- Malignant Pleural Mesothelioma - Pipeline by EnGeneIC Ltd, H2 2015
- Malignant Pleural Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Five Prime Therapeutics, Inc., H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Genelux Corporation, H2 2015
- Malignant Pleural Mesothelioma - Pipeline by GlaxoSmithKline Plc, H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Juno Therapeutics Inc., H2 2015
- Malignant Pleural Mesothelioma - Pipeline by MedImmune, LLC, H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Merck & Co., Inc., H2 2015
- Malignant Pleural Mesothelioma - Pipeline by MolMed S.p.A., H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Morphotek, Inc., H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Novartis AG, H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Oxford BioMedica Plc, H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Pfizer Inc., H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Pharma Mar, S.A., H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Synta Pharmaceuticals Corp., H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Verastem, Inc., H2 2015
- Malignant Pleural Mesothelioma - Pipeline by Virttu Biologics Limited, H2 2015
- Assessment by Monotherapy Products, H2 2015
- Number of Products by Stage and Target, H2 2015
- Number of Products by Stage and Mechanism of Action, H2 2015
- Number of Products by Stage and Route of Administration, H2 2015
- Number of Products by Stage and Molecule Type, H2 2015
- Malignant Pleural Mesothelioma Therapeutics - Recent Pipeline Updates, H2 2015
- Malignant Pleural Mesothelioma - Dormant Projects, H2 2015
- Malignant Pleural Mesothelioma - Discontinued Products, H2 2015
- List of Figures
- Number of Products under Development for Malignant Pleural Mesothelioma, H2 2015
- Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Number of Products under Investigation by Universities/Institutes, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Assessment by Monotherapy Products, H2 2015
- Number of Products by Top 10 Targets, H2 2015
- Number of Products by Stage and Top 10 Targets, H2 2015
- Number of Products by Top 10 Mechanism of Actions, H2 2015
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
- Number of Products by Top 10 Routes of Administration, H2 2015
- Number of Products by Stage and Top 10 Routes of Administration, H2 2015
- Number of Products by Top 10 Molecule Types, H2 2015
- Number of Products by Stage and Top 10 Molecule Types, H2 2015
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook